India Pharma Outlook Team | Thursday, 19 November 2026
Bispecific antibodies for cancer are gaining attention as pharmaceutical companies explore more selective approaches to tumour treatment.
AbbVie has entered a strategic collaboration with Germany-based DISCO Pharmaceuticals, committing USD 40 million upfront and up to USD 2.5 billion in potential milestone payments to discover and develop next-generation AND-gated bispecific therapeutics for solid tumours.
The agreement combines DISCO's cancer-cell surface mapping technology with AbbVie's oncology research capabilities.
The partnership aims to identify tumour-specific protein combinations that could help distinguish cancer cells from healthy tissue, addressing a major challenge in targeted cancer treatment.
Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships
Unlike conventional antibodies that bind to one target, bispecific antibodies can recognize two targets simultaneously.
DISCO's AND-gated approach is designed to bind cancer cells only when both selected proteins are present, potentially reducing damage to healthy tissue.
This strategy could address challenges in treating solid tumours, where cancer-associated proteins may also occur in normal cells. DISCO is developing candidates for small-cell lung and colorectal cancers, with a development candidate expected to be selected in the second half of 2027.
The partnership strengthens AbbVie's pipeline of bispecific antibodies for cancer. DISCO will lead discovery, while AbbVie can exclusively license selected programs for further development after specified research activities.
In January 2026, AbbVie paid China's RemeGen USD 650 million upfront for rights outside China to a bispecific medicine targeting solid tumours.
The collaboration reflects growing interest of pharmaceutical companies in antibody-based cancer treatments.
AbbVie reported third-quarter 2026 revenue of USD 17.404 billion, up 10.3 percent year-on-year. Its oncology portfolio generated USD 1.696 billion, growing 0.8 percent.
The company raised its full-year adjusted EPS guidance to USD 13.95-USD 13.99. AbbVie shares closed at USD 286.01 on November 18, down 2.33 percent during the session.
The company's continued investment in bispecific antibodies for cancer reflects its effort to expand its oncology pipeline alongside its existing commercial portfolio.